Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic...

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Genetics

Background:

• Cardiac hypertrophy is a significant complication of hypertension, often leading to lethal outcomes.
• Atrial natriuretic peptide (ANP) is hypothesized to have local antihypertrophic effects within the heart.
• The role of the ANP receptor guanylyl cyclase-A (GC-A) in cardiac hypertrophy development in vivo remains unclear.

Purpose of the Study:

• To investigate the local function of the ANP/GC-A system in modulating cardiomyocyte growth.
• To determine if cardiomyocyte-specific GC-A inactivation contributes to cardiac hypertrophy.

Main Methods:

• Utilized homologous loxP/Cre-mediated recombination to selectively inactivate the GC-A gene in cardiomyocytes.
• Created genetically modified mice to bypass systemic effects seen in germline GC-A inactivation.
• Assessed cardiac hypertrophy markers, blood pressure, and cardiac function following aortic constriction.

Main Results:

• Mice with cardiomyocyte-restricted GC-A deletion showed mild cardiac hypertrophy and increased expression of hypertrophy markers.
• Elevated systemic ANP levels and reduced blood pressure were observed in these mice.
• Enhanced hypertrophic responses and cardiac dysfunction were noted after aortic constriction.

Conclusions:

• The ANP/GC-A system locally moderates the molecular program of cardiac hypertrophy in cardiomyocytes.
• Loss of GC-A in cardiomyocytes promotes cardiac hypertrophy and impairs cardiac function, especially under stress.
• This study provides in vivo evidence for a critical local role of ANP signaling in preventing cardiac hypertrophy.